Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-Induced Ocular Hypertensive Monkeys

Fuwa M., Toris C.B., Fan S., Taniguchi T., Ichikawa M., Odani-Kawabata N., Iwamura R., Yoneda K., Matsugi T., Shams N.K., Zhang J.-Z.

2018
Journal of Ocular Pharmacology and Therapeutics

View publication

Therapeutic Area

Glaucoma
Categories

Preclinical development

Affiliations

RandD Division, Santen Pharmaceutical Co. Ltd., 8916-16 Takayama-cho, Ikoma-shi Nara, 630-0101, Japan; Department of Ophthalmology, Nebraska Medical Center, University of Nebraska Medical Center, Omaha, NE, United States; Department of Ophthalmology, Case Western Reserve University, Cleveland, OH, United States; RandD Division, Santen Pharmaceutical Co. Ltd., Osaka, Japan; Pharmaceuticals Research Laboratory, Pharmaceutical Division, Ube Industries, Ltd., Yamaguchi, Japan; RandD Division, Santen Inc., Emeryville, CA, United States

Related Publications

Associations between Clustered Visual Field Progression and Locations of Disc Hemorrhages in Glaucoma: A Three-year Prospective Study

Akagi T.; Fukuchi T.; Higashide T.; Udagawa S.; Ohkubo S.; Sugiyama K.; Tanihara H.; Araie M.; Tomita G.; Matsumoto C.; Tomidokoro A.; Hangai M.; Kawata H.; Inai M.; Tanaka Y.; SVF Prospector Study Group

Proteome-Wide Analysis of Autoantibodies in Open-Angle Glaucoma in Japanese Population: A Pilot Study

Takada N.; Ishikawa M.; Sato K.; Kunikata H.; Ninomiya T.; Hanyuda A.; Fukuda E.; Yamaguchi K.; Ono C.; Kirihara T.; Shintani C.; Tsusu C.; Osanai A.; Goshima N.; Izumi Y.; Zorumski C.F.; Nakazawa T.

Bioequivalence of Preservative-free and Preserved Omidenepag Isopropyl (OMDI) 0.002% Ophthalmic Solutions in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: Results from the Phase 3 DAISY Study

Aihara M.; Lu F.; Ikeda T.; Odani-Kawabata N.

View all Glaucoma publications